Teva Pharmaceutical Industries Limited has successfully shifted its strategy, leveraging its generics business to fund growth in specialty medicines, driving a turnaround in performance. TEVA's "Pivot ...

The generic product is now available nationwide in strengths of 0.3mg, 0.45mg, 0.625mg, 0.9mg, and 1.25mg. The Food and Drug Administration (FDA) has approved the first generic version of Premarin ® ...

The 2025 NFL season is more than halfway complete with Week 10 in the books and Week 11 already upon us. The playoff picture isn't finalized, but it's certainly taking shape as we near the home ...

At launch, Black Ops 7 will feature nine Wildcards. These unique abilities are designed to ultimately change how you plan and build your loadout, as certain Wildcards allow you to spawn with extra ...

Trading card manufacturer Wild Card filed a lawsuit Thursday alleging rival card maker Panini America violated federal and Texas antitrust laws. Wild Card’s lawsuit alleges Panini has been ...

Panini America has been named the defendant in a lawsuit filed by Wild Card in a court filing that was filed today. The briefing outlines accusations of violating federal laws such as the Sherman Anti ...

A sign outside the Panini Group factory in Modena, Italy. Marco Bertorello / AFP via Getty Images Wild Card, a Tennessee-based trading card manufacturer known for its autographed cards featuring top ...

The US Food and Drug Administration will take steps to streamline the development of generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to accelerate ...

The 2025 MLS Cup Playoffs finish on Dec. 6. / Zach Sanderson/ISI Photos/Getty Images The 2025 MLS Cup playoffs are nearly here, and the schedule for the first portions of the postseason has been ...

Jamie Dimon is right to be alarmed about our national-security vulnerabilities, especially an overreliance on China and India for generic prescription drugs (“Investments for National Security,” op-ed ...

The last 12 months have been a bit boring for Novartis AG (NYSE:NVS) and have resulted in a lack of my coverage updates on the company. The stock has delivered a total return of around 18% since my ...